Jasper Therapeutics, Inc. Board of Directors

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Mr. Ronald A. Martell

Mr. Ronald A. Martell

President, CEO & Director

Mr. Matthew Ford

Mr. Matthew Ford

Vice President of Human Resources

Dr. Wendy Pang M.D., Ph.D.

Dr. Wendy Pang M.D., Ph.D.

Senior Vice President of Research & Translational Medicine

Ms. Patricia Carlos

Ms. Patricia Carlos

Senior Vice President of Regulatory Affairs & Quality

Dr. Luca Di Noto Ph.D.

Dr. Luca Di Noto Ph.D.

Senior Vice President of Technical Operations

Mr. Herbert C. Cross CPA

Mr. Herbert C. Cross CPA

CFO & Corporate Secretary

Mr. David Ku M.D.

Mr. David Ku M.D.

Vice President of Corporate Development, Portfolio Strategy & Management

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.